Drugs /

progesterone

Back to Drugs List

Overview

Trade Name(s):
Prometrium
NCI Definition [1]:
Produced in the corpus luteum and by the placenta, as an antagonist of estrogens. Promotes proliferation of uterine mucosa and the implantation of the blastocyst, prevents further follicular development.

Clinical Trials

View Clinical Trials for progesterone

Progesterone has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating progesterone, 1 is phase 2 (1 open).

ER Expression, ER Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for progesterone clinical trials.

Breast carcinoma is the most common disease being investigated in progesterone clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Progesterone
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating progesterone and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
gelbkoerperhormon, (s)-progesterone, progesteronum, pregnenedione, corpus luteum hormone, (s)-4-pregnene-3,20-dione, progesterone [chemical/ingredient], progesterone, progesterona, lutogynon, progestérone, 17α-progesterone, progesteron, delta(4)-pregnene-3,20-dione, delta4-pregnene-3,20-dione, 17alpha-progesterone, (s)-pregn-4-en-3,20-dione, pregn-4-ene-3,20-dione, Prometrium
NCIT ID [1]:
C2297

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.